HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pier Luigi Zinzani Selected Research

ibritumomab tiuxetan (Zevalin)

11/2019Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up.
6/201690-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.
3/2014Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
8/2010Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.
11/2008Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
4/2008Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
2/2008A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
7/2007Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pier Luigi Zinzani Research Topics

Disease

75Lymphoma (Lymphomas)
12/2022 - 05/2002
56Hodgkin Disease (Hodgkin's Disease)
04/2022 - 08/2002
47Non-Hodgkin Lymphoma (Lymphosarcoma)
08/2022 - 08/2002
42Neoplasms (Cancer)
03/2022 - 02/2002
33B-Cell Lymphoma (Lymphoma, B Cell)
01/2022 - 12/2002
32Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2022 - 03/2005
30Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
12/2022 - 11/2003
21Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
10/2022 - 05/2005
16B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
08/2022 - 01/2004
15Disease Progression
12/2021 - 08/2011
13Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
10/2022 - 07/2012
13Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/2022 - 09/2005
13Neutropenia
12/2021 - 01/2004
9Thrombocytopenia (Thrombopenia)
01/2021 - 12/2006
9T-Cell Lymphoma (Lymphoma, T Cell)
01/2020 - 05/2005
8Mycosis Fungoides
01/2022 - 09/2005
8Hairy Cell Leukemia
01/2022 - 03/2004
8Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
01/2022 - 05/2002
7Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
10/2022 - 01/2012
6Peripheral Nervous System Diseases (PNS Diseases)
12/2021 - 08/2011
6Cardiotoxicity
01/2021 - 07/2012
6Anemia
10/2019 - 01/2004
5Hematologic Neoplasms (Hematological Malignancy)
01/2022 - 11/2016
4Waldenstrom Macroglobulinemia (Macroglobulinemia)
08/2022 - 10/2018
4Diarrhea
12/2021 - 10/2012
4Hypertension (High Blood Pressure)
11/2021 - 10/2020
4Nausea
11/2021 - 09/2006
4Pneumonia (Pneumonitis)
01/2021 - 08/2011
4Hemorrhage
12/2020 - 09/2006
3Fever (Fevers)
01/2022 - 08/2011
3Fatigue
01/2022 - 09/2016
3Cytokine Release Syndrome
01/2022 - 12/2020
3Residual Neoplasm
01/2021 - 10/2009
3Exanthema (Rash)
01/2021 - 09/2016
3Atrial Fibrillation
12/2020 - 10/2018
3Febrile Neutropenia
12/2020 - 09/2006

Drug/Important Bio-Agent (IBA)

45Rituximab (Mabthera)FDA Link
12/2022 - 09/2003
37Brentuximab VedotinIBA
04/2022 - 08/2013
22Doxorubicin (Adriamycin)FDA LinkGeneric
10/2022 - 02/2005
19Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2022 - 05/2004
17Lenalidomide (CC 5013)FDA Link
01/2022 - 08/2011
15Vincristine (Oncovin)FDA LinkGeneric
10/2022 - 05/2004
15Pharmaceutical PreparationsIBA
01/2022 - 12/2008
15fludarabineIBA
06/2016 - 01/2004
14Prednisone (Sone)FDA LinkGeneric
10/2022 - 05/2004
14ibrutinibIBA
10/2022 - 03/2017
12Mitoxantrone (Novantrone)FDA LinkGeneric
06/2016 - 07/2004
11pembrolizumabIBA
01/2022 - 11/2016
11Monoclonal AntibodiesIBA
01/2022 - 03/2014
11AnthracyclinesIBA
01/2022 - 11/2003
9Bendamustine HydrochlorideFDA Link
12/2022 - 07/2012
9Bleomycin (Blenoxane)FDA LinkGeneric
11/2021 - 06/2008
8idelalisibIBA
01/2022 - 03/2014
8Biological ProductsIBA
01/2022 - 01/2012
8Vinblastine (Vinblastine Sulfate)FDA Link
11/2021 - 06/2008
8Dacarbazine (DIC)FDA LinkGeneric
11/2021 - 06/2008
8ibritumomab tiuxetan (Zevalin)FDA Link
11/2019 - 07/2007
8Bortezomib (Velcade)FDA Link
01/2018 - 09/2007
7pixantrone (BBR 2778)IBA
01/2021 - 09/2006
7Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
12/2018 - 10/2006
7Etoposide (VP 16)FDA LinkGeneric
08/2017 - 08/2002
6Agammaglobulinaemia Tyrosine KinaseIBA
10/2022 - 01/2018
6CladribineFDA LinkGeneric
01/2022 - 03/2004
6copanlisibIBA
11/2021 - 03/2017
6Proteins (Proteins, Gene)FDA Link
01/2021 - 01/2003
5Methotrexate (Mexate)FDA LinkGeneric
12/2021 - 10/2009
5mogamulizumabIBA
12/2021 - 03/2016
5LigandsIBA
12/2021 - 09/2016
5Phosphotransferases (Kinase)IBA
11/2021 - 03/2015
5GemcitabineFDA Link
08/2017 - 12/2005
510-propargyl-10-deazaaminopterinFDA Link
07/2017 - 07/2010
5romidepsin (FK228)FDA Link
01/2017 - 03/2016
5Yttrium-90IBA
08/2010 - 07/2007
4Biosimilar PharmaceuticalsIBA
08/2022 - 12/2017
4Immune Checkpoint InhibitorsIBA
01/2022 - 01/2017
4NivolumabIBA
12/2021 - 09/2016
4liposomal doxorubicin (Doxil)FDA Link
10/2020 - 01/2015
4Alkylating AgentsIBA
01/2017 - 01/2003
4IfosfamideFDA LinkGeneric
04/2016 - 08/2002
3tafasitamabIBA
01/2022 - 11/2021
3Biomarkers (Surrogate Marker)IBA
01/2022 - 05/2013
3loncastuximab tesirineIBA
01/2022 - 01/2021
3Bexarotene (LGD1069)FDA Link
12/2021 - 07/2017
3venetoclaxIBA
01/2021 - 03/2017
3AnthraquinonesIBA
01/2021 - 07/2012
3AntibodiesIBA
09/2020 - 08/2004
3obinutuzumabIBA
09/2020 - 10/2015
3acalabrutinibIBA
02/2020 - 01/2018

Therapy/Procedure

80Therapeutics
12/2022 - 02/2002
46Drug Therapy (Chemotherapy)
01/2022 - 08/2002
26Stem Cell Transplantation
04/2022 - 04/2003
11Radiotherapy
11/2021 - 12/2002
11Radioimmunotherapy
05/2020 - 02/2008
8Salvage Therapy
01/2021 - 02/2004
7Autologous Transplantation
04/2022 - 05/2003
6Bone Marrow Transplantation (Transplantation, Bone Marrow)
02/2015 - 01/2005
5Immunotherapy
12/2021 - 02/2008
4Homologous Transplantation
01/2021 - 08/2012
3Hematopoietic Stem Cell Transplantation
01/2021 - 01/2005
3Drug Tapering
12/2020 - 08/2013